Biosergen is a biotech company focused on developing innovative antifungal drugs to address severe invasive fungal infections. Founded to translate breakthroughs from SINTEF and The University of Science and Technology in Trondheim, Norway, Biosergen aims to meet the unmet medical needs in this critical field. With a strong board of directors and a dedicated team, the company is driven by a compelling business vision and model.

At Biosergen, our primary focus is on the development of BSG005, a promising pipeline drug for the treatment of invasive fungal diseases. We are committed to advancing scientific research and have published numerous publications to contribute to the knowledge surrounding fungal infections. As an investor-friendly company, Biosergen provides clear information on its rights issue, stock information, and IPO filings.

Fungal infections are a silent crisis and often go unnoticed. Biosergen is determined to raise awareness and find effective solutions to combat this emerging disaster. We prioritize patient well-being and work towards improving the lives of those affected by fungal infections.

Contact us to learn more about our mission and join us in this crucial fight